Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Nov 14

PMID 31717773

Citations 44

Authors

Verena Martini

Sylvia Timme-Bronsert

Stefan Fichtner-Feigl

Jens Hoeppner

Birte Kulemann

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related death in the USA and Europe; early symptoms and screenings are lacking, and it is usually diagnosed late with a poor prognosis. Circulating tumor cells (CTCs) have been promising new biomarkers in solid tumors. In the last twenty years (1999-2019), 140 articles have contained the key words "Circulating tumor cells, pancreatic cancer, prognosis and diagnosis." Articles were evaluated for the use of CTCs as prognostic markers and their correlation to survival in pancreatic ductal adenocarcinoma (PDAC). In the final selected 17 articles, the CTC detection rate varied greatly between different enrichment methodologies and ranged from 11% to 92%; the majority of studies used the antigen-dependent CellSearch system for CTC detection. Fifteen of the reviewed studies showed a correlation between CTC presence and a worse overall survival. The heterogeneity of CTC-detection methods and the lack of uniform results hinder a comparison of the evaluated studies. However, CTCs can be detected in pancreatic cancer and harbor a hope to serve as an early detection tool. Larger studies are needed to corroborate CTCs as valid biomarkers in pancreatic cancer.

Citing Articles

Plasma treatment can efficiently increase the attachment of pancreatic circulatory tumor cells to the surface.

Mahdian S, Mahmoudi-Aznaveh A, Mousavi S, Larijani B, Azizi Z, Javar H Discov Oncol. 2025; 16(1):222.

PMID: 39982607 PMC: 11845332. DOI: 10.1007/s12672-025-01988-4.

Patient-derived xenografts from circulating cancer stem cells as a preclinical model for personalized pancreatic cancer research.

Wagner B, Ettner-Sitter A, Ihlo N, Behr M, Koelbl S, Brunner S Sci Rep. 2025; 15(1):2896.

PMID: 39843495 PMC: 11754431. DOI: 10.1038/s41598-025-87054-z.

Nanomaterial-based detection of circulating tumor cells and circulating cancer stem cells for cancer immunotherapy.

Yun Y, Kim S, Lee S, Cho H, Choi J Nano Converg. 2024; 11(1):56.

PMID: 39671082 PMC: 11645384. DOI: 10.1186/s40580-024-00466-x.

Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic Cancer.

Patel R, Parappilly M, Farley H, Latour E, Wang L, Nair A Cancers (Basel). 2024; 16(21).

PMID: 39518088 PMC: 11545756. DOI: 10.3390/cancers16213650.

Circulating tumor cells in pancreatic cancer: more than liquid biopsy.

Li Z, Qin C, Zhao B, Li T, Zhao Y, Zhang X Ther Adv Med Oncol. 2024; 16:17588359241284935.

PMID: 39421679 PMC: 11483845. DOI: 10.1177/17588359241284935.

References

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Soeth E, Grigoleit U, Moellmann B, Roder C, Schniewind B, Kremer B . Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J Cancer Res Clin Oncol. 2005; 131(10):669-76. DOI: 10.1007/s00432-005-0008-1. View

Sefrioui D, Blanchard F, Toure E, Basile P, Beaussire L, Dolfus C . Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer. 2017; 117(7):1017-1025. PMC: 5625666. DOI: 10.1038/bjc.2017.250. View

de Albuquerque A, Kubisch I, Ernst D, Breier G, Stamminger G, Fersis N . Development of a molecular multimarker assay for the analysis of circulating tumor cells in adenocarcinoma patients. Clin Lab. 2012; 58(5-6):373-84. View

Pailler E, Faugeroux V, Oulhen M, Mezquita L, Laporte M, Honore A . Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in -Rearranged Non-Small-Cell Lung Cancer. Clin Cancer Res. 2019; 25(22):6671-6682. DOI: 10.1158/1078-0432.CCR-19-1176. View

Ignatiadis M, Litiere S, Rothe F, Riethdorf S, Proudhon C, Fehm T . Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. Ann Oncol. 2018; 29(8):1777-1783. DOI: 10.1093/annonc/mdy211. View

Jakabova A, Bielcikova Z, Pospisilova E, Matkowski R, Szynglarewicz B, Staszek-Szewczyk U . Molecular characterization and heterogeneity of circulating tumor cells in breast cancer. Breast Cancer Res Treat. 2017; 166(3):695-700. PMC: 5680374. DOI: 10.1007/s10549-017-4452-9. View

Kulemann B, Rosch S, Seifert S, Timme S, Bronsert P, Seifert G . Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. Sci Rep. 2017; 7(1):4510. PMC: 5495768. DOI: 10.1038/s41598-017-04601-z. View

Becker A, Hernandez Y, Frucht H, Lucas A . Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol. 2014; 20(32):11182-98. PMC: 4145757. DOI: 10.3748/wjg.v20.i32.11182. View

10.

Gao Y, Zhu Y, Zhang Z, Zhang C, Huang X, Yuan Z . Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization. J Exp Clin Cancer Res. 2016; 35:66. PMC: 4828870. DOI: 10.1186/s13046-016-0340-0. View

11.

Cohen J, Javed A, Thoburn C, Wong F, Tie J, Gibbs P . Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A. 2017; 114(38):10202-10207. PMC: 5617273. DOI: 10.1073/pnas.1704961114. View

12.

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

13.

Ankeny J, Court C, Hou S, Li Q, Song M, Wu D . Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Br J Cancer. 2016; 114(12):1367-75. PMC: 4984454. DOI: 10.1038/bjc.2016.121. View

14.

Okubo K, Uenosono Y, Arigami T, Mataki Y, Matsushita D, Yanagita S . Clinical impact of circulating tumor cells and therapy response in pancreatic cancer. Eur J Surg Oncol. 2017; 43(6):1050-1055. DOI: 10.1016/j.ejso.2017.01.241. View

15.

Fujii T, Reuben J, Huo L, Fernandez J, Gong Y, Krupa R . Androgen receptor expression on circulating tumor cells in metastatic breast cancer. PLoS One. 2017; 12(9):e0185231. PMC: 5619732. DOI: 10.1371/journal.pone.0185231. View

16.

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

17.

Trapp E, Janni W, Schindlbeck C, Juckstock J, Andergassen U, de Gregorio A . Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. J Natl Cancer Inst. 2018; 111(4):380-387. DOI: 10.1093/jnci/djy152. View

18.

Yu K, Ricigliano M, Hidalgo M, Abou-Alfa G, Lowery M, Saltz L . Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. Clin Cancer Res. 2014; 20(20):5281-9. PMC: 4346320. DOI: 10.1158/1078-0432.CCR-14-0531. View

19.

Bissolati M, Sandri M, Burtulo G, Zorzino L, Balzano G, Braga M . Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer. Tumour Biol. 2014; 36(2):991-6. DOI: 10.1007/s13277-014-2716-0. View

20.

Konigsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F . Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol. 2011; 50(5):700-10. DOI: 10.3109/0284186X.2010.549151. View